Researchers presented new findings Saturday at a breast-cancer symposium here suggesting that the risks associated with anthracyclines, a class of chemotherapy drugs widely used to treat the disease, outweighed their benefits in some patients.The findings renewed a debate over whether anthracyclines, which have been around since the 1960s, should remain the standard of care in treating breast cancer, or whether newer drugs should be used more frequently instead.
More...



Flanked by top health officials including Health Secretary Robert F. Kennedy Jr., President Trump unveiled a...
Respiratory therapist Marcy Freeman doesn't need a research study to confirm for her a return to...
Cases of cyclosporiasis, a parasitic infection known for causing explosive diarrhea, have now reached 47 states...





























